Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized neoadjuvant letrozole versus tamoxifen in postmenopausal women with ER-positive breast cancer
2007-000900-34Phase 3Active
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Femara neoadjuvant monotherapy with Tamoxifen neoadjuvant monotherapy (2 arms). Primary endpoints: Ki67 after 4 months and PCNA after 4 months. Started Aug 2010; status: active.
02
Drugs
letrozoletamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-000900-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000900-34.